ArticleCancer gene therapy2005
Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Article in Cancer gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2008Trial
- Human Cancer and Platelet Interaction, a Potential Therapeutic Target.International journal of molecular sciences · 2018Review
- A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.Oncotarget · 2015Article
- Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme.BioMed research international · 2015Review
- Article
- Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10.Oncoimmunology · 2012Article
- Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.Oncoimmunology · 2012Article
- NK cells: key to success of DC-based cancer vaccines?The oncologist · 2012Review
- Engineering dendritic cells to enhance cancer immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Review
- New approaches to the development of adenoviral dendritic cell vaccines in melanoma.Current opinion in investigational drugs (London, England : 2000) · 2010Review
- Article
- Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands.Cancer immunology, immunotherapy : CII · 2007Review
- Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice.Cancer immunology, immunotherapy : CII · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Tumor antigen gene-modified dendritic cells (DC) generates robust antigen-specific protective antitumor responses. Though the role of CD4 positive and CD8 positive cells in the immunological response to gene-modified DC has been well-characterized, the role of NK cells in this response has been somewhat less clear. Owing to the significant contribution of innate immunity in other model systems, we postulated that NK cells would hold a critical position in the generation of an immune response following immunization with tumor antigen-engineered DC. Immunization with MART-1 melanoma antigen-engineered DC in C57BL/6 mice resulted in the generation of antigen-specific cytotoxic T lymphocytes and in vivo protective responses to the murine B16 melanoma. These responses were dependent on the presence of functional NK cells, although NK cells alone were not sufficient in generating protective responses. Adoptive transfer of NK cells into an NK-deficient but T-cell-competent environment restored the protective response to gene-modified DC immunization. In conclusion, protective immunity after tumor antigen gene-modified DC immunization requires collaboration between CD4+ and CD8+ T cells and NK cells.
Indexed as
Identifiers
15775996What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.